Virological response after short-term CCR5 antagonist exposure in HIV-infected patients: Frequency of subjects with virological response and associated factors

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 10, 2011, Pages 4664-4669

  Ruiz Mateos, Ezequiel ^a   González Serna, Alejandro ^a   Genebat, Miguel ^a   Machmach, Kawthar ^a   Vidal, Francesc ^b   Muñoz Fernández, Ángeles ^c   Ferrando Martinez, Sara ^a,c   Leal, Manuel ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CXCR4; MARAVIROC; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DRUG EXPOSURE; ECOTROPIC VIRUS; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE; VIRAL PHENOMENA AND FUNCTIONS; VIROLOGICAL RESPONSE; VIRUS ISOLATION; VIRUS LOAD; VIRUS STRAIN;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; CYCLOHEXANES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; RECEPTORS, CCR5; RECEPTORS, CXCR4; RNA, VIRAL; TRIAZOLES; VIRAL LOAD;

EID: 80052841044     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00753-11     Document Type: Article

References (25)

1. Berger, E. A., et al. 1998. A new classification for HIV-1. Nature 391:240.
2. Chueca, N., et al. 2009. Improvement in the determination of HIV-1 tropism using the V3 gene sequence and a combination of bioinformatic tools. J. Med. Virol. 81:763-767.
3. Cooper, D. A., et al. 2010. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J. Infect. Dis. 201:803-813.
4. Dorr, P., et al. 2005. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 49:4721-4732.
5. Fiser, A. L., et al. 21 September 2010, posting date. High CD4+ T-cell surface CXCR4 density as a risk factor for R5 to X4 switch in the course of HIV-1 infection. J. Acquir. Immune Defic. Syndr. [Epub ahead of print.]
6. Genebat, M., et al. 2011. Discordance rates between Trofile test and short-term virological response to maraviroc. Antiviral Res. 89:182-185.
7. Genebat, M., et al. 2009. Correlation between the Trofile(R) test and virological response to a short-term maraviroc exposure in HIV-infected patients. J. Antimicrob. Chemother. 64:845-849.
8. Genebat, M., et al. 2010. Long-term immunovirological effect and tolerability of a maraviroc-containing regimen in routine clinical practice. Curr. HIV Res. 8:482-486.
9. Gonzalez-Serna, A., et al. 2010. TROCAI (tropism coreceptor assay information): a new phenotypic tropism test and its correlation with Trofile enhanced sensitivity and genotypic approaches. J. Clin. Microbiol. 48:4453-4458.
10. Hammer, S. M., et al. 2008. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society - USA Panel. JAMA 300:555-570.
11. Koot, M., et al. 1993. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann. Intern. Med. 118:681-688.
12. Landovitz, R. J., et al. 2008. Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection. J. Infect. Dis. 198:1113-1122.
13. Lin, Y. L., et al. 2005. CXCR4 overexpression during the course of HIV-1 infection correlates with the emergence of X4 strains. J. Acquir. Immune Defic. Syndr. 39:530-536.
14. Low, A. J., et al. 2007. Current V3 genotyping algorithms are inadequate for predicting X4 co-receptor usage in clinical isolates. AIDS 21:F17-F24. (Pubitemid 47329758)
15. Mills, A., et al. 2010. Once-daily maraviroc (MVC) + atazanavir/ritonavir (ATV/r) versus emtricitabine/tenofovir (TDF/FTC) + ATV/r in treatment naïve patients: a week 24 planned interim analysis, abstr. THLBB203. Abstr. XVIII Int. AIDS Conf.
16. Moreno, S., et al. 2009. Prevalence of CCR5-tropic HIV-1 among treatment-experienced individuals in Spain. HIV Clin. Trials 10:394-402.
17. Poveda, E., et al. 2009. Design and validation of new genotypic tools for easy and reliable estimation of HIV tropism before using CCR5 antagonists. J. Antimicrob. Chemother. 63:1006-1010.
18. Raymond, S., et al. 2008. Correlation between genotypic predictions based on V3 sequences and phenotypic determination of HIV-1 tropism. AIDS 22:F11-F16.
19. Ribeiro, R. M., M. D. Hazenberg, A. S. Perelson, and M. P. Davenport. 2006. Naive and memory cell turnover as drivers of CCR5-to-CXCR4 tropism switch in human immunodeficiency virus type 1: implications for therapy. J. Virol. 80:802-809.
20. Schurmann, D., et al. 2007. Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults. AIDS 21:1293-1299. (Pubitemid 46883483)
21. Sierra-Madero, J., et al. 2010. Efficacy and safety of maraviroc versus efavirenz, both with zidovudine/lamivudine: 96-week results from the MERIT study. HIV Clin. Trials 11:125-132.
22. Swenson, L. C., et al. 2011. Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment- experienced patients. J. Infect. Dis. 203:237-245.
23. Waters, L., et al. 2008. The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen. Clin. Infect. Dis. 46:1617-1623.
24. Whitcomb, J. M., et al. 2007. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob. Agents Chemother. 51:566-575.
25. Wilkin, T. J., et al. 2011. Reanalysis of coreceptor tropism in HIV-1-infected adults using a phenotypic assay with enhanced sensitivity. Clin. Infect. Dis. 52:925-928.